MajesTEC-5: High MRD-Negative Rates With Talquetamab Combo in Newly Diagnosed Myeloma | IMS 2026

Leo Rasche, MD, of University Hospital Würzburg discusses early MajesTEC-5 results with talquetamab, daratumumab and lenalidomide before stem cell transplant at IMS 2026 in Glasgow. In 20 newly diagnosed patients, the combination produced very high response and MRD-negativity rates. He explains how talquetamab's GPRC5D target may mean fewer infections than BCMA bispecifics, and the side effects patients should know about, including frequent taste loss and skin and nail changes.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity

Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:

0:00 Introduction

0:30 The MajesTEC-5 trial

0:57 What is talquetamab?

1:31 Infection risk vs. BCMA bispecifics

2:04 Results: 90% response and MRD negativity

3:21 Side effects: taste, nails and skin